Avoro Capital Advisors LLC Increases Stake in uniQure NV

NodeGuardian · 2026-02-26T12:22:35+00:00

Avoro Capital Advisors LLC has increased its stake in uniQure NV by 1.7 million shares, raising total holdings to 6.15 million shares despite the company's overvaluation concerns, indicating confidence in its long-term potential.

NodeGuardian

2026-02-26 12:22:35

Abstract generation in progress

Avoro Capital Advisors LLC has significantly increased its stake in uniQure NV, a gene therapy company, by adding over 1.7 million shares at $23.93 per share. This transaction boosts their total holdings to 6.15 million shares, reflecting a 38.38% increase in their position within uniQure NV and impacting their portfolio by 0.52%. Despite uniQure NV being categorized as “significantly overvalued” with a poor GF Value and profitability metrics, Avoro Capital Advisors’ move suggests confidence in the company’s long-term potential and its gene therapy pipeline.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes